[{"AccountsPayableAndAccruedLiabilitiesCurrent_0_Q2_USD":9393000.0,"NotesReceivableNet_0_Q2_USD":13528928000.0,"OperatingIncomeLoss_1_Q2_USD":744949000.0,"OperatingIncomeLoss_2_Q2_USD":974247000.0,"OtherAssetsCurrent_0_Q2_USD":12098000.0,"OtherAssetsNoncurrent_0_Q2_USD":5960000.0,"OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_1_Q2_USD":0.0,"OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_2_Q2_USD":0.0,"NotesReceivableGross_0_Q2_USD":14819532000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":-7274000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_1_Q2_USD":3231000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_2_Q2_USD":8112000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1_Q2_USD":-4043000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2_Q2_USD":-9528000.0,"OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_1_Q2_USD":13299000.0,"OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_2_Q2_USD":28790000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":6025000.0,"OtherComprehensiveIncomeLossNetOfTax_2_Q2_USD":-17640000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":11150000.0,"NotesAndLoansReceivableNetNoncurrent_0_Q2_USD":12932077000.0,"NonoperatingIncomeExpense_2_Q2_USD":-8513000.0,"LongTermDebtNoncurrent_0_Q2_USD":5825559000.0,"MinorityInterest_0_Q2_USD":4671686000.0,"MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_1_Q2_USD":170808000.0,"MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_2_Q2_USD":316186000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":-451085000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-473134000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":1057820000.0,"NotesAndLoansReceivableNetCurrent_0_Q2_USD":596851000.0,"NetIncomeLoss_1_Q2_USD":440776000.0,"NetIncomeLossAttributableToNoncontrollingInterest_1_Q2_USD":365979000.0,"NetIncomeLossAttributableToNoncontrollingInterest_2_Q2_USD":455839000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q2_USD":440776000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_2_Q2_USD":509895000.0,"NetIncomeLossAvailableToCommonStockholdersDiluted_1_Q2_USD":653737000.0,"NetIncomeLossAvailableToCommonStockholdersDiluted_2_Q2_USD":761401000.0,"NonoperatingIncomeExpense_1_Q2_USD":61806000.0,"NetIncomeLoss_2_Q2_USD":509895000.0,"LongTermDebtCurrent_0_Q2_USD":0.0,"OtherLiabilitiesCurrent_0_Q2_USD":4314000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":-107000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":5763000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":2291966000.0,"Revenues_1_Q2_USD":554963000.0,"Revenues_2_Q2_USD":1127990000.0,"ShareBasedCompensation_2_Q2_USD":1434000.0,"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0_Q2_USD":10405365000.0,"StockholdersEquityOther_1_Q2_USD":0.0,"ResearchAndDevelopmentExpense_1_Q2_USD":3122000.0,"StockholdersEquityOther_2_Q2_USD":0.0,"StockIssuedDuringPeriodValueShareBasedCompensation_2_Q2_USD":1434000.0,"TradingSecuritiesDebt_0_Q2_USD":842685000.0,"TransferOfInvestments_2_Q2_USD":0.0,"TreasuryStockValue_0_Q2_USD":2662000.0,"UnrealizedGainLossOnDerivatives_2_Q2_USD":-4464000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":607163000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":607151000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q2_USD":721000.0,"OtherNoncashIncomeExpense_2_Q2_USD":-2049000.0,"RepaymentsOfLongTermDebt_2_Q2_USD":0.0,"ProvisionForLoanAndLeaseLosses_2_Q2_USD":48499000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":-65000.0,"PaymentsOfDebtIssuanceCosts_2_Q2_USD":0.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_2_Q2_USD":35170000.0,"PaymentsToAcquireEquityMethodInvestments_2_Q2_USD":17427000.0,"PaymentsToAcquireFinanceReceivables_2_Q2_USD":683741000.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":728025000.0,"PaymentsToMinorityShareholders_2_Q2_USD":238197000.0,"ProvisionForLoanLossesExpensed_2_Q2_USD":35232000.0,"ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_2_Q2_USD":523000.0,"ProceedsFromIssuanceInitialPublicOffering_2_Q2_USD":0.0,"ProceedsFromIssuanceOfLongTermDebt_2_Q2_USD":0.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_2_Q2_USD":868689000.0,"ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_2_Q2_USD":31250000.0,"ProfitLoss_1_Q2_USD":806755000.0,"ProfitLoss_2_Q2_USD":965734000.0,"ProvisionForLoanAndLeaseLosses_1_Q2_USD":-243762000.0,"ProceedsFromInterestReceived_2_Q2_USD":2332000.0,"LongTermDebt_0_Q2_USD":5825559000.0,"LiabilitiesCurrent_0_Q2_USD":283989000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":16514913000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":500367000.0,"CostsAndExpenses_1_Q2_USD":-189986000.0,"CostsAndExpenses_2_Q2_USD":153743000.0,"DebtInstrumentUnamortizedDiscount_0_Q2_USD":174441000.0,"DebtSecuritiesAvailableForSaleUnrealizedGainLoss_1_Q2_USD":14015000.0,"DebtSecuritiesAvailableForSaleUnrealizedGainLoss_2_Q2_USD":23130000.0,"DerivativeNotionalAmount_0_Q2_USD":600000000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":436733000.0,"DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_1_Q2_USD":212961000.0,"DividendsCash_1_Q2_USD":72581000.0,"DividendsCash_2_Q2_USD":138564000.0,"DividendsCommonStockCash_2_Q2_USD":138600000.0,"DueToRelatedPartiesCurrent_0_Q2_USD":117378000.0,"DueToRelatedPartiesNoncurrent_0_Q2_USD":117378000.0,"EarningsPerShareBasic_1_Q2_USD":1.08,"EarningsPerShareBasic_2_Q2_USD":1.28,"DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_2_Q2_USD":251506000.0,"EarningsPerShareDiluted_1_Q2_USD":1.08,"CommonStockDividendsPerShareCashPaid_2_Q2_USD":0.17,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":133601000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":28672000.0,"AdditionalPaidInCapital_0_Q2_USD":3415598000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":1700000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":900000.0,"AmortizationOfFinancingCostsAndDiscounts_2_Q2_USD":9583000.0,"AmortizationOfIntangibleAssets_2_Q2_USD":11404000.0,"AmortizationOfIntangibleAssets_1_Q2_USD":5733000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"Assets_0_Q2_USD":16514913000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":92819000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":178381000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":271200000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q2_USD":68702000.0,"AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0_Q2_USD":202498000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":1142281000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":1142281000.0,"AssetsCurrent_0_Q2_USD":2707454000.0,"EarningsPerShareDiluted_2_Q2_USD":1.25,"EquityMethodInvestmentDividendsOrDistributions_2_Q2_USD":22003000.0,"EquityMethodInvestments_0_Q2_USD":465620000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_Q2_USD":-913000.0,"IncreaseDecreaseInInterestPayableNet_2_Q2_USD":758000.0,"IncreaseDecreaseInOtherCurrentAssets_2_Q2_USD":-3703000.0,"IncreaseDecreaseInOtherCurrentLiabilities_2_Q2_USD":2730000.0,"IncreaseDecreaseInOtherNoncurrentAssets_2_Q2_USD":0.0,"IncrementalCommonSharesAttributableToContingentlyIssuableShares_1_Q2_shares":197773000.0,"IncrementalCommonSharesAttributableToContingentlyIssuableShares_2_Q2_shares":207508000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":0.0,"IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1_Q2_shares":46000.0,"InterestExpense_1_Q2_USD":37426000.0,"InterestExpense_2_Q2_USD":74841000.0,"InterestPaidNet_2_Q2_USD":64500000.0,"InterestPayableCurrent_0_Q2_USD":42904000.0,"InvestmentIncomeNet_1_Q2_USD":14037000.0,"InvestmentIncomeNet_2_Q2_USD":30635000.0,"Liabilities_0_Q2_USD":6109548000.0,"IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2_Q2_shares":37000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":0.0,"IncomeLossFromEquityMethodInvestments_2_Q2_USD":15783000.0,"IncomeLossFromEquityMethodInvestments_1_Q2_USD":17701000.0,"EquitySecuritiesFVNINoncurrent_0_Q2_USD":184042000.0,"EquitySecuritiesFvNiUnrealizedGainLoss_1_Q2_USD":55495000.0,"EquitySecuritiesFvNiUnrealizedGainLoss_2_Q2_USD":1309000.0,"FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_1_Q2_USD":-28300000.0,"FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss_2_Q2_USD":10700000.0,"FinancingReceivableAllowanceForCreditLosses_0_Q2_USD":1290604000.0,"FinancingReceivableChangeInPresentValueExpenseReversal_2_Q2_USD":-21719000.0,"FiniteLivedIntangibleAssetsAccumulatedAmortization_0_Q2_USD":588954000.0,"FiniteLivedIntangibleAssetsGross_0_Q2_USD":606216000.0,"FiniteLivedIntangibleAssetsNet_0_Q2_USD":17262000.0,"GainLossOnDerivativeInstrumentsNetPretax_1_Q2_USD":-1909000.0,"GainLossOnDerivativeInstrumentsNetPretax_2_Q2_USD":-4464000.0,"GainsLossesOnExtinguishmentOfDebt_2_Q2_USD":0.0,"GeneralAndAdministrativeExpense_1_Q2_USD":44921000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":88077000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":806755000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":965734000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":409344000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":399606000.0,"Ticker":"RPRX","CIK":"1802768","name":"ROYALTY PHARMA PLC","OfficialName":"Royalty Pharma plc Class A Ordinary Shares ","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"19213987432.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210811"}]